SingapOre Lung Cancer Screening Through Integrating CT With Other Biomarkers (SOLSTICE)

What this Trial Is About

Researchers are evaluating the feasibility of using low dose CT (LDCT) screening combined with biomarker testing to detect lung cancer in at-risk populations in Singapore. This single arm cohort study focuses on both smokers and non-smokers who have risk factors such as family history of lung cancer. The goal is to understand how well LDCT screening can be implemented locally and to gather baseline data especially for lung adenocarcinoma in never-smokers, a group unique to East Asia. The study follows guidelines from the Academy of Medicine, Singapore and uses Lung CT Screening Reporting & Data System (Lung-RADS) to report results. Participants will undergo LDCT scans and provide blood samples for biomarker assays at each screening visit. Additional samples such as urine, saliva, and breath may also be collected. Based on the Lung-RADS score assigned from the scan results, participants will be grouped and managed accordingly. Those with scores of 2 or higher will be referred for further follow-up and clinical evaluation up to five years, while those with a score of 1 will be monitored with screening surveillance ending after two years if no nodules are found. During the study, detailed information on participants’ demographics, smoking history, environmental exposures, family history, tuberculosis history, and comorbidities will be collected. Participants will be monitored through scans, blood draws, and other sample collections over the study period. Researchers will measure the feasibility of LDCT screening at baseline and up to two years afterward while providing clinical surveillance and management for participants with suspicious findings. The total age range for participation is 50 to 80 years, with a target of 650 non-smokers and 350 smokers.

SingapOre Lung Cancer Screening Through Integrating CT With Other biomarkErs (SOLSTICE)